science wire

« BACK

Pharmacology



Results 301 - 350 of 1331.
« Previous 1 ... 3 4 5 6 7 8 9 10 11 ... 27 Next »


Health - Pharmacology - 27.08.2018
Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah (tisagenlecleucel)
The EC approval is based on the first global CAR-T registration trials, which included patients from eight European countries and demonstrated durable responses and a consistent safety profile in r/r

Pharmacology - Health - 20.08.2018
China National Drug Administration grants rapid approval of Roche’s Alecensa (alectinib) as a treatment for ALK-positive lung cancer
China National Drug Administration grants rapid approval of Roche's Alecensa (alectinib) as a treatment for ALK-positive lung cancer Approval follows priority review of Alecensa in China, just eight

Health - Pharmacology - 03.08.2018
PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease
European Medicines Agency PRIME (PRIority MEdicines) status is granted to medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options RG6042 has the potential to be the first therapy targeting the underlying cause of Huntington's disease, a fatal neurodegenerative rare disease Third PRIME designation for a Roche medicine Roche today announced that the European Medicines Agency (E

Health - Pharmacology - 31.07.2018

Pharmacology - Health - 30.07.2018
Novartis marks a new era for migraine patients with the EU approval of Aimovig , a first-of-its-kind treatment specifically designed for migraine prevention
Novartis marks a new era for migraine patients with the EU approval of Aimovig , a first-of-its-kind treatment specifically designed for migraine prevention Patients on Aimovig (erenumab) in clinical

Health - Pharmacology - 27.07.2018
Novartis combination Tafinlar + Mekinist receives positive CHMP opinion for adjuvant treatment of BRAF V600 mutation-positive melanoma
Phase III trial showed a 53% reduction in risk of recurrence or death with the combination of a BRAF and MEK inhibitor as adjuvant therapy versus placebo Relapse-free survival benefit with Tafinlar

Health - Pharmacology - 23.07.2018
Novartis renews drug donation of Egaten (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke
Novartis extends agreement with the WHO for the donation of Egaten for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 millio

Pharmacology - Health - 20.07.2018
Roche to present new data demonstrating the breadth and depth of its Alzheimer’s programme at the upcoming Alzheimer’s Association International Conference
Roche to present new data demonstrating the breadth and depth of its Alzheimer's programme at the upcoming Alzheimer's Association International Conference Late-breaking Phase II exploratory analysis

Health - Pharmacology - 20.07.2018
FDA grants Breakthrough Device Designation for Roche’s Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer’s disease
FDA grants Breakthrough Device Designation for Roche's Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer's disease Roche announced today, that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Elecsys ß-Amyloid (1-42) CSF and Elecsys Phospho-Tau (181P) CSF.

Pharmacology - Health - 19.07.2018
Roche’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with advanced lung cancer
Roche today announced that the Phase III IMpower132 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of Tecentriq (atezolizumab) plus chemoth

Health - Pharmacology - 18.07.2018
Novartis Kisqali now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
Novartis Kisqali now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women Kisqal

Pharmacology - Business / Economics - 18.07.2018
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
Net sales grew 5% (cc , +7% USD) mainly driven by: Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU Entresto sales more than doubled to USD 239 millio

Pharmacology - Health - 18.07.2018
FDA grants Breakthrough Therapy Designation for Roche’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC)
FDA grants Breakthrough Therapy Designation for Roche's Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC) Roche today announced t

Health - Pharmacology - 02.07.2018
Roche commences tender offer for all shares of Foundation Medicine, Inc. for US$ 137.00 per share in cash
Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Foundation Medicine, Inc.

Health - Pharmacology - 02.07.2018
Phase III IMpassion130 study showed Roche’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer
First Phase III immunotherapy study to demonstrate a statistically significant improvement in progression-free survival (PFS) in the intention-to-treat (ITT) and PD-L1 positive first-line metastatic

Health - Pharmacology - 29.06.2018
Novartis receives positive CHMP opinion for Kymriah for treating two aggressive blood cancers, marking important medical advance for patients in Europe
Novartis receives positive CHMP opinion for Kymriah for treating two aggressive blood cancers, marking important medical advance for patients in Europe First CHMP opinion for a CAR-T cell therapy in

Pharmacology - Health - 28.06.2018
Novartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig (erenumab) in patients with chronic and episodic migraine
Novartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig (erenumab) in patients with chronic and episodic migraine Results from a one-year study of efficacy and

Health - Pharmacology - 26.06.2018
Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin
Survey data published in JEADV show that patients experienced four different treatments and three medical professionals on average before finding an efficacious therapy New publication also highlight

Pharmacology - Health - 25.06.2018
Roche’s TECENTRIQ in combination with chemotherapy helped people with previously-untreated extensive-stage small cell lung cancer live significantly longer compared to chemotherapy
IMpower133 is the first Phase III study with an immunotherapy-based combination to show improvement in overall survival and progression-free survival in the initial treatment of extensive-stage small

Health - Pharmacology - 19.06.2018
Roche and Foundation Medicine reach definitive merger agreement to accelerate broad availability of comprehensive genomic profiling in oncology
Together, the companies will leverage expertise in genomics and molecular information to enhance the development of personalised medicines and care for patients with cancer Merger focuses on driving

Health - Pharmacology - 18.06.2018
Novartis International AG: Alcon AcrySof IQ PanOptix trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery
Novartis International AG: Alcon AcrySof IQ PanOptix trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery Better visual outcomes for patients with t

Health - Pharmacology - 16.06.2018
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
Overall response rate was 52% and median duration of response was not reached at a median follow-up of 14 months, signifying responses were durable Patients had a 65% chance of being relapse-free o

Health - Pharmacology - 15.06.2018
Study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer
Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer Comparison of Jakavi (ruxolitinib) vs.

Health - Pharmacology - 15.06.2018
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients’ quality of life
Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%) About two-thirds of patients

Pharmacology - Health - 13.06.2018
FDA approves Roche’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery
FDA approves Roche's Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery Avastin is now approved for ten distinct uses across six different types of cancer in the United States Roche today announced that the US Food and Drug Administration (FDA) has approved Avastin (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as a single agent, for the treatment of women with advanced (stage III or IV) ovarian cancer following initial surgical resection.

Pharmacology - Health - 11.06.2018
Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia
Approval based on phase III MURANO study showing Venclexta plus Rituxan reduced risk of disease progression or death by 81% compared to bendamustine plus Rituxan Roche , announced today that the Unit

Pharmacology - Health - 07.06.2018
Novartis announces JCO publication of Lutathera NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs
Novartis announces JCO publication of Lutathera NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs Patients repor

Pharmacology - Health - 05.06.2018
FDA grants Priority Review to Roche’s Hemlibra for people with haemophilia A without factor VIII inhibitors
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Hemlibra (emicizumab-kxwh) for adults and children with haemophilia A without factor VIII inhibitors.

Pharmacology - Health - 02.06.2018
Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer
Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell

Health - Pharmacology - 30.05.2018
FDA expedites review of Novartis drug Promacta for first-line severe aplastic anemia (SAA)
Promacta receives FDA Priority Review for first-line treatment of SAA based on data showing 52% complete response rate and 85% overall response rate when added to standard immunosuppressive therapy (

Pharmacology - Health - 29.05.2018
Phase III IMpower130 study showed Roche’s Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to chemotherapy alone
Phase III IMpower130 study showed Roche's Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to

Health - Pharmacology - 28.05.2018
Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto
Novartis International AG: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto Overall summary score was also significantly higher for Entresto patients than for patients not taking Entresto, as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12) These improvements were reported early by Entresto patients, with a median follow-up time of 32 days 21&

Pharmacology - Health - 21.05.2018
Roche’s Hemlibra reduced treated bleeds by 96 percent compared to no prophylaxis in phase III HAVEN 3 study in haemophilia A without factor VIII inhibitors
In a subset of patients in the HAVEN 3 study who previously received factor VIII prophylaxis, the standard of care, Hemlibra reduced bleeds by 68 percent compared to their prior therapy Phase III HAV

Pharmacology - Health - 18.05.2018
Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention
Migraine is a severe neurologic disease that profoundly impacts millions of patients in the United States Aimovig is the first and only FDA-approved treatment to block the calcitonin gene-related p

Pharmacology - Health - 17.05.2018
Novartis data at ASCO and EHA reinforce company’s commitment to reimagining cancer
Results from the Kisqali MONALEESA clinical trial program, the largest industrysponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will be pre

Pharmacology - Health - 17.05.2018
Phase III IMpower150 study showed Roche’s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin plus carboplatin and paclitaxel
A survival advantage for the Tecentriq and Avastin combination regimen was observed in all pre-specified exploratory patient subgroups analysed, including people with EGFR and ALK mutations, liver me

Pharmacology - Life Sciences - 16.05.2018
Cellular Valve Structure Opens Up Potential Novel Therapies
Cellular Valve Structure Opens Up Potential Novel Therapies
Human cells are enclosed by membranes and are in osmotic equilibrium with their environment. If the concentration of solute molecules (osmolarity) in the fluid surrounding the cells decreases, cells start to swell; in extreme cases, this can result in the cells bursting.

Business / Economics - Pharmacology - 16.05.2018

Pharmacology - Health - 14.05.2018
Roche to present new phase III data for Hemlibra in people with haemophilia A at the World Federation of Hemophilia 2018 World Congress
Data include results from HAVEN 3 study in people with haemophilia A without factor VIII inhibitors and HAVEN 4 study in people with haemophilia A with or without factor VIII inhibitors Ongoing Hemli

Pharmacology - Health - 12.05.2018
Novartis announces FDA approval of Gilenya as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
New approval for Gilenya (fingolimod) addresses strong unmet need for younger patients, who often experience more frequent relapses than adults with multiple sclerosis (MS) In a landmark controlled

Pharmacology - Health - 10.05.2018
Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer
Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer Roche today announc

Pharmacology - Health - 07.05.2018
FDA grants priority review to Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer
FDA grants priority review to Roche's cancer immunotherapy TECENTRIQ (atezolizumab) for initial treatment of people with a specific type of metastatic lung cancer Roche today announced that the US Fo
« Previous 1 ... 3 4 5 6 7 8 9 10 11 ... 27 Next »

This site uses cookies and analysis tools to improve the usability of the site. More information. |